Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years

  • Technology appraisal guidance
  • TA554
  • Published: 

This guidance has been updated and replaced by NICE technology appraisal guidance 975.